Business Wire

ADVA

11.5.2021 09:02:06 CEST | Business Wire | Press release

Share
ADVA adds encryption to flagship 10G edge device

ADVA (FSE: ADV) today launched its FSP 150-XG118Pro (CSH) , addressing urgent enterprise demand for high-bandwidth connectivity with robust security. The new member of the ADVA FSP 150 programmable demarcation and edge compute portfolio supports 10Gbit/s MEF 3.0 Carrier Ethernet and IP services, provides precise synchronization capabilities and now features hardware-based encryption. With its comprehensive MACsec security, the ADVA FSP 150-XG118Pro (CSH) enables business data to pass safely and seamlessly across untrusted public networks and empowers communication service providers (CSPs) to offer fully encrypted bandwidth services. What’s more, like ADVA’s FSP 3000 transport solution, the ADVA FSP 150-XG118Pro (CSH) is ready to run post-quantum cryptographic (PQC) algorithms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005059/en/

“Our FSP 150-XG118Pro (CSH) provides a simple and affordable route to high-capacity Carrier Ethernet connectivity with the highest levels of data protection. Unique in our industry, this compact and cost-efficient device combines demarcation, edge compute, synchronization and encryption,” said James Buchanan, GM, Edge Cloud, ADVA. “No other single solution offers all the features of our FSP 150-XG118Pro (CSH). Straight out of the box, it delivers data encryption compliant with the strictest standards in the industry, including FIPS 140-3. Our FSP 150-XG118Pro (CSH) has multi-layer demarcation capabilities as well as precise synchronization delivery. What’s more, its edge computing capabilities and open SDN control make it a key component for industrial IoT applications.”

The ADVA FSP 150-XG118Pro (CSH) combines 10Gbit/s MEF 3.0 Carrier Ethernet and IP service demarcation and aggregation with a rich set of programmability, synchronization and security features. For the first time, CSPs and businesses can deploy a compact and power-efficient solution with next-generation synchronization delivery, NFV-hosting capabilities and robust data protection. The FSP 150-XG118Pro (CSH) features precise clock technology based on Synchronous Ethernet and hardware processing of IEEE 1588 timestamps. Its fully open architecture supports ADVA’s Ensemble Connector and other virtual network function infrastructure. And, based on an enhanced version of MACsec able to encrypt across multiple domains and service provider networks, it provides end-to-end security across MEF Layer 2 cloud networks.

“Our FSP 150-XG118Pro (CSH) supports a smooth and simple transition from 1Gbit/s to 10Gbit/s services while meeting the very highest security requirements. Now there’s a simple and affordable way to achieve the safe and assured connectivity that businesses need for peace of mind and compliance with stringent regulations. The solutions also enables CSPs to roll out tailored encryption-as-a-service offerings,” commented Eli Angel, VP, product line management, ADVA. “Our FSP 150-XG118Pro (CSH) shares the same security framework as our optical products. Its cryptographic techniques, including dynamic key exchange and hardware tamper protection, ensure the safety of the most sensitive data. And, like our FSP 3000, it’s ready to support quantum-safe key exchange via a simple software upgrade.”

Watch this video for more information on the new FSP 150-XG118Pro (CSH): https://youtu.be/efdEFASaue8 .

Further details are also available in these slides: https://adva.li/fsp-150-xg118pro-csh-slides .


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye